Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 5, 2013, Pages 600-607

  Gupta, Shashank ^a,b   Tyagi, Sandeep ^a   Almeida, Deepak V ^a,c   Maiga, Mariama C ^a,b   Ammerman, Nicole C ^a,c   Bishai, William R ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

Author keywords

Efflux; Human equivalent doses; Mycobacterium tuberculosis; Verapamil

Indexed keywords

RIFAMPICIN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; MOUSE; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT DURATION; TUBERCULOSIS;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTITUBERCULAR AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED C3H; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; RIFAMPIN; TIME FACTORS; TUBERCULOSIS, PULMONARY; VERAPAMIL;

EID: 84883514966     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201304-0650OC     Document Type: Article

References (35)

1. World Health Organization. Global tuberculosis control 2011. Geneva: WHO Press; 2011.
2. Paige C, Bishai WR. Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol 2010;12: 301-309.
3. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: An update. Drugs 2009;69:1555-1623.
4. Adams KN, Takaki K, Connolly LE, WiedenhoftH, Winglee K, HumbertO, Edelstein PH, Cosma CL, Ramakrishnan L. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 2011;145:39-53.
5. Huang TSKC, Wang HM, Yan BS, Huang SP, Chen YS, Lee SSJ, Syu WJ. Inhibition of the Mycobacterium tuberculosis reserpine-sensitive efflux pump augments intracellular concentrations of ciprofloxacin and enhances susceptibility of some clinical isolates. J Formos Med Assoc (In press).
6. Gupta S, Salam N, Srivastava V, Singla R, Behera D, Khayyam KU, Korde R, Malhotra P, Saxena R, Natarajan K. Voltage gated calcium channels negatively regulate protective immunity to mycobacterium tuberculosis. PLoS One 2009;4:e5305.
7. De Rossi E, Ainsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: An unresolved question. FEMS Microbiol Rev 2006;30: 36-52.
8. Gupta AK, Katoch VM, Chauhan DS, Sharma R, Singh M, Venkatesan K, Sharma VD. Microarray analysis of efflux pump genes in multidrugresistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb Drug Resist 2010;16:21-28.
9. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011;184:269-276.
10. Morris RP, Nguyen L, Gatfield J, Visconti K, Nguyen K, Schnappinger D, Ehrt S, Liu Y, Heifets L, Pieters J, et al. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2005;102:12200-12205.
11. Viveiros M, Portugal I, Bettencourt R, Victor TC, Jordaan AM, Leandro C, Ordway D, Amaral L. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:2804-2810.
12. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006;19:382-402.
13. Fontan PA, Aris V, Alvarez ME, Ghanny S, Cheng J, Soteropoulos P, Trevani A, Pine R, Smith I. Mycobacterium tuberculosis sigma factor E regulon modulates the host inflammatory response. J Infect Dis 2008;198:877-885.
14. Nguyen L, Thompson CJ. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol 2006;14: 304-312.
15. Ramon-Garcia S, Martin C, Thompson CJ, Ainsa JA. Role of the Mycobacterium tuberculosis p55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother 2009;53:3675-3682.
16. Rohde KH, Abramovitch RB, Russell DG. Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe 2007;2:352-364.
17. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 2003;198:693-704.
18. Zahner D, Zhou X, Chancey ST, Pohl J, Shafer WM, Stephens DS. Human antimicrobial peptide LL-37 induces MefE/Mel-mediated macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2010;54:3516-3519.
19. Kamath AB, Alt J, Debbabi H, Behar SM. Toll-like receptor 4-defective C3H/HeJ mice are not more susceptible than other C3H substrains to infection with Mycobacterium tuberculosis. Infect Immun 2003;71:4112-4118.
20. Chytil L, Strauch B, Cvacka J, Maresova V, Widimsky J Jr, Holaj R, Slanar O. Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: Application to document non-compliance of patients. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:3167-3173.
21. Lee YS, Yoon JN, Yoon IS, Lee MG, Kang HE. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407. Xenobiotica 2012;42:766-774.
22. Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, et al. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci USA 2012; 109:15001-15005.
23. Dhillon J, Dickinson JM, Sole K, Mitchison DA. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996;40: 552-555.
24. John DN, Fort S, Lewis MJ, Luscombe DK. Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers. Br J Clin Pharmacol 1992;33:623-627.
25. Barbarash RA. Verapamil-rifampin interaction. Drug Intell Clin Pharm 1985;19:559-560.
26. Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL. Near-total reduction in verapamil bioavailability by rifampin: electrocardiographic correlates. Chest 1988;94:954-959.
27. Maiga M, Agarwal N, Ammerman NC, Gupta R, Guo H, Maiga MC, Lun S, Bishai WR. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS ONE 2012;7:e30749.
28. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193.
29. Machado D, Couto I, Perdigao J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, Viveiros M. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS ONE 2012;7:e34538.
30. Neal RA, van Bueren J, McCoy NG, IwobiM. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. Trans R Soc Trop Med Hyg 1989;83:197-198.
31. Martin SK, Oduola AM, Milhous WK. Reversal of chloroquine resistance in plasmodium falciparum by verapamil. Science 1987;235:899-901.
32. Mooy J, Böhm R, van Baak M, van Kemenade J, vd Vet A, Rahn KH. The influence of antituberculosis drugs on the plasma level of verapamil. Eur J Clin Pharmacol 1987;32:107-109.
33. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. Noninvasive pulmonary [18F]-2-fluoro-deoxyd- glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 2009;53:4879-4884.
34. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, PomperMG, Nuermberger EL, Jain SK. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 2012; 205:595-602.
35. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 2009;53:4178-4184.